目的 探討心可舒丸聯(lián)合曲美他嗪治療冠心病心絞痛的臨床療效。方法 選取2017年6月-2019年6月南陽醫(yī)學(xué)高等專科學(xué)校第一附屬醫(yī)院收治的冠心病心絞痛患者128例，隨機(jī)分為對照組（64例）和治療組（64例）。對照組口服鹽酸曲美他嗪片，20 mg/次，3次/d。治療組在對照組基礎(chǔ)上口服心可舒丸，4粒/次，3次/d。兩組患者均治療1個月。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者內(nèi)皮素-1（ET-1）和一氧化氮（NO）水平，及心絞痛發(fā)作持續(xù)時(shí)間和次數(shù)。結(jié)果 治療后，對照組臨床有效率和心電圖有效率分別為81.25%和75.00%，分別顯著低于治療組的93.75%和92.19%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組ET-1明顯下降（P<0.05），而NO明顯升高（P<0.05），且治療組ET-1和NO水平明顯好于對照組（P<0.05）。治療后，兩組心絞痛發(fā)作次數(shù)明顯減少（P<0.05），發(fā)作持續(xù)時(shí)間明顯縮短（P<0.05），且治療組心絞痛發(fā)作持續(xù)時(shí)間和次數(shù)小于對照組（P<0.05）。結(jié)論 心可舒丸聯(lián)合曲美他嗪治療冠心病心絞痛，可有效改善患者心絞痛癥狀，療效確切，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical effect of Xinkeshu Pills combined with trimetazidine in treatment of angina pectoris of coronary heart disease. Methods Patients (128 cases) with angina pectoris of coronary heart disease in the First Affiliated Hospital of Nanyang Medical College from June 2017 to June 2019 were randomly divided into control (64 cases) and treatment (64 cases) groups. Patients in the control group were po administered with Trimetazidine Hydrochloride Tablets, 20 mg/time, three times daily. Patients in the treatment group were po administered with Xinkeshu Pills on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacy was evaluated, and the level of ET-1 and NO, and duration and frequency of angina attack in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and electrocardiographic effect in the control group were 81.25% and 75.00%, which were significantly lower than 93.75% and 92.19% in the treatment group, respectively, and there were differences between two groups (P < 0.05). After treatment, the ET-1 levels in two groups were significantly decreased (P < 0.05), but NO levels were significantly increased (P < 0.05), and the ET-1 and NO in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the frequency of angina attack in two groups was significantly decreased (P < 0.05), duration of angina attack in two groups was significantly shortened (P < 0.05), and the duration and frequency of angina attack in the treatment group were significantly less than that in the control group (P < 0.05). Conclusion Xinkeshu Pills combined with trimetazidine in treatment of angina pectoris of coronary heart disease can effectively improve the symptoms of angina pectoris, which has a certain clinical application value.

R972

河南省科技發(fā)展計(jì)劃項(xiàng)目（182102510123）